OCEA (Ocean Biomedical) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2025)


What is Ocean Biomedical ROE % Adjusted to Book Value?

Ocean Biomedical OCEA -75.00% ROE % Adjusted to Book Value is 0.00% as of Mar. 2025.

Ocean Biomedical's ROE % for the quarter that ended in Mar. 2025 was 0.00%. Ocean Biomedical's PB Ratio for the quarter that ended in Mar. 2025 was N/A. Ocean Biomedical's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 was N/A.

Ocean Biomedical ROE % Adjusted to Book Value Related Terms

Ocean Biomedical ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Ocean Biomedical's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocean Biomedical ROE % Adjusted to Book Value Chart

Ocean Biomedical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Ocean Biomedical Quarterly Data
Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Equity 0.00 0.00 Negative Equity 0.00

OCEA vs SIGY, ENDV, SCPX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Ocean Biomedical's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ocean Biomedical ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocean Biomedical's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Ocean Biomedical's ROE % Adjusted to Book Value falls into.


Ocean Biomedical ROE % Adjusted to Book Value Calculation

Ocean Biomedical's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Ocean Biomedical's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Ocean Biomedical (OCEA) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ocean Biomedical and its competitors.
Is Ocean Biomedical's ROE % Adjusted to Book Value too high?
Ocean Biomedical's current ROE % Adjusted to Book Value is 0.00%.
How does Ocean Biomedical's ROE % Adjusted to Book Value compare to SIGY and ENDV?
Ocean Biomedical's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Ocean Biomedical and its competitors. Ocean Biomedical's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocean Biomedical stock overvalued right now?
Ocean Biomedical (OCEA) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Ocean Biomedical (OCEA), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ocean Biomedical Business Description

Address 55 Claverick Street, Room 325, Providence, RI, USA, 02903
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.